- Home
- MNMD vs STOK Comparison
MNMD vs STOK Comparison
Compare MNMD & STOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MNMD
- STOK
- Stock Information
- Founded
- MNMD 2019
- STOK 2014
- Country
- MNMD United States
- STOK United States
- Employees
- MNMD N/A
- STOK N/A
- Industry
- MNMD Pharmaceuticals and Biotechnology
- STOK Biotechnology: Pharmaceutical Preparations
- Sector
- MNMD Health Care
- STOK Health Care
- Exchange
- MNMD Nasdaq
- STOK Nasdaq
- Market Cap
- MNMD 559.5M
- STOK 556.7M
- IPO Year
- MNMD N/A
- STOK 2019
- Fundamental
- Price
- MNMD $6.31
- STOK $8.11
- Analyst Decision
- MNMD Strong Buy
- STOK Strong Buy
- Analyst Count
- MNMD 9
- STOK 8
- Target Price
- MNMD $25.75
- STOK $23.83
- AVG Volume (30 Days)
- MNMD 2.5M
- STOK 716.9K
- Earning Date
- MNMD 03-06-2025
- STOK 05-05-2025
- Dividend Yield
- MNMD N/A
- STOK N/A
- EPS Growth
- MNMD N/A
- STOK N/A
- EPS
- MNMD N/A
- STOK N/A
- Revenue
- MNMD N/A
- STOK $16,742,999.00
- Revenue This Year
- MNMD N/A
- STOK $111.92
- Revenue Next Year
- MNMD N/A
- STOK $72.11
- P/E Ratio
- MNMD N/A
- STOK N/A
- Revenue Growth
- MNMD N/A
- STOK 81.08
- 52 Week Low
- MNMD $5.03
- STOK $5.60
- 52 Week High
- MNMD $12.22
- STOK $17.58
- Technical
- Relative Strength Index (RSI)
- MNMD 41.01
- STOK 40.32
- Support Level
- MNMD $5.96
- STOK $7.65
- Resistance Level
- MNMD $6.77
- STOK $8.21
- Average True Range (ATR)
- MNMD 0.51
- STOK 0.48
- MACD
- MNMD -0.07
- STOK 0.08
- Stochastic Oscillator
- MNMD 27.31
- STOK 58.55
About MNMD Mind Medicine (MindMed) Inc.
Mind Medicine Inc is a biopharmaceutical company. The company produces to treat brain health disorders. The company discovers, develops, and deploys psychedelic inspired medicines and therapies to address addiction and mental illness. The company is assembling a compelling drug development pipeline of treatments based on psychedelic substances. The firm is having an approach towards developing the next generation of psychedelic-inspired medicines and therapies.
About STOK Stoke Therapeutics Inc.
Stoke Therapeutics Inc is engaged in addressing the underlying causes of severe diseases by upregulating protein expression with RNA-based medicines. Using its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, it is developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its first compound, STK-001, is in clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. The company primarily operates in the U.S.